Potential Survival Benefit of Adjuvant Chemotherapy in Stage IV Intrahepatic Cholangiocarcinoma: A Multicenter, Stage-Stratified Analysis.

ABSTRACT:

Background

The survival benefit of adjuvant chemotherapy (AC) in intrahepatic cholangiocarcinoma (ICC) remains uncertain, particularly in advanced-stage disease.

Methods

We retrospectively analyzed 480 patients who underwent curative-intent hepatic resection for ICC at eight institutions between 2006 and 2023. Patients were stratified by receipt of AC, and survival outcomes were compared across LCSGJ stages. Multivariable Cox regression was used to identify prognostic factors.

Results

Among 480 patients, 206 received AC. While AC did not significantly improve survival in stage I-III disease, it was associated with significantly longer overall survival (median 25.5 vs. 17.1 months, p = 0.008) and recurrence-free survival (median 10.3 vs. 6.0 months, p = 0

SUBMITTER: Kosaka H 

PROVIDER: S-EPMC12757147 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature